about
PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cellsTwo domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cellsThe inhibition of p85αPI3KSer83 phosphorylation prevents cell proliferation and invasion in prostate cancer cells.The p85α regulatory subunit of PI3K mediates cAMP-PKA and retinoic acid biological effects on MCF7 cell growth and migration.Antineoplastic activity of povidone-iodine on different mesothelioma cell lines: results of in vitro study.Non-transcriptional action of oestradiol and progestin triggers DNA synthesis.Two Different Serum MiRNA Signatures Correlate with the Clinical Outcome and Histological Subtype in Pleural Malignant Mesothelioma Patients.Expression of cancer stem cell biomarkers as a tool for a correct therapeutic approach to hepatocellular carcinoma.Rapid signalling pathway activation by androgens in epithelial and stromal cells.Cytokines and VEGF induction in orthodontic movement in animal models.pEGFR-Tyr 845 expression as prognostic factors in oral squamous cell carcinoma: a tissue-microarray study with clinic-pathological correlationsAndrogen-stimulated DNA synthesis and cytoskeletal changes in fibroblasts by a nontranscriptional receptor action.The value of matrix metalloproteinase-9 and vascular endothelial growth factor receptor 1 pathway in diagnosing indeterminate pleural effusion.Integrating signals between cAMP and MAPK pathways in breast cancer.A missense mutation in CASK causes FG syndrome in an Italian familyAnimal models in studies of cardiotoxicity side effects from antiblastic drugs in patients and occupational exposed workersInduction of proinflammatory cytokines in human osteoblastic cells by Chlamydia pneumoniae.Towards gene therapy for deafness.Current treatment of cutaneous squamous cancer and molecular strategies for its sensitization to new target-based drugs.Glix 13, a new drug acting on glutamatergic pathways in children and animal models of autism spectrum disordersAlphaVBeta5 integrins mediates Pseudomonas fluorescens interaction with A549 cellsTumor Microenvironment Versus Cancer Stem Cells in Cholangiocarcinoma: Synergistic Effects?Translational Research and Plasma Proteomic in Cancer.Multifaceted Breast Cancer: The Molecular Connection With Obesity.Circulating Tumor Cells in Diagnosing Lung Cancer: Clinical and Morphologic Analysis.The role of E-cadherin down-regulation in oral cancer: CDH1 gene expression and epigenetic blockage.Interplay between steroid receptors and neoplastic progression in sarcoma tumors.Role of atypical protein kinase C in estradiol-triggered G1/S progression of MCF-7 cells.Inhibition of estradiol receptor/Src association and cell growth by an estradiol receptor alpha tyrosine-phosphorylated peptide.Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in diagnosis of pleural effusion of malignant origin.Crosstalk between EGFR and extranuclear steroid receptors.Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action.cAMP signaling selectively influences Ras effectors pathways.Protein tyrosine phosphorylation and estradiol action.p85 regulatory subunit of PI3K mediates cAMP-PKA and estrogens biological effects on growth and survival.pRb2/p130 localizes to the cytoplasm in diffuse gastric cancer.Epigenetic fingerprint in endometrial carcinogenesis: the hypothesis of a uterine field cancerization.Biomarker discovery by plasma proteomics in familial Brugada Syndrome.A proteomics-driven assay defines specific plasma protein signatures in different stages of Ménière's disease.Proteomics in Ménière disease.
P50
Q28363087-B71F83D8-0749-4D64-9F45-6B8F7D8AF718Q28771752-638DA3BF-A694-444F-80FD-6FAA0E34C718Q30009887-A99D47D9-2F51-44D6-9C60-EA034E68F02AQ30010160-E3FD9344-0A4A-4DA8-9CF4-C19F309F6FADQ33686933-8C018B93-9167-49E7-BB98-1193216991B3Q33890864-09FBEF3D-34FE-4CEB-969C-F3DC7A9FE70EQ35742519-8B98D097-7D86-40AA-8DCD-73B99AE6C626Q35745018-FFF04020-F71C-430F-9A3E-F04A203A3C97Q35853373-DA7855A7-34D9-498A-87AB-248446FE0ACCQ35991187-CC75C4D1-FA46-478D-8BDE-7238D7884DA2Q36289932-07A31F72-AD04-49E7-84A1-F84AA18E0CC3Q36323480-245D9BAB-F3F9-4749-A82F-368A5D3A40B8Q36599672-1A657F36-6D41-4D8A-AFF3-8EDBFD3FC751Q36992104-6ACC3772-D1F4-43FF-852E-E71C4F08AA54Q37156077-6A4FF965-764B-451A-9ABF-BEFF85B25EC0Q37631325-E8B447F5-DB2E-411F-BB7E-B5877800EFA7Q37850475-7EDED92E-7E88-4FBC-ACAD-311BB4C31A19Q37906432-A78BE527-8E11-4655-930F-E2FF57B3C561Q38045433-B587AC3F-999F-44BF-A52A-CDB28D045343Q38194145-903A36C3-6A0B-4B50-A50D-D06FA39B4CAFQ38309999-BE893775-3369-4BC9-A346-5AF120C7C77CQ38584340-EDF53E99-3F65-4C03-8893-FB3D4DC41FBBQ38610869-7C005932-0708-45C9-B890-B48F31B6DABAQ38882124-991B14B5-D7F4-489B-8E12-3397B47C6DFBQ39039363-3DAECD41-C2CB-4137-873B-7E6134E31F72Q39055490-06CE5EF7-8924-46BE-A36E-495E4130B6D3Q39596152-5C82A82D-A798-4C0A-BD76-D8209313A4E1Q39756674-4FBB9168-4DEA-438F-A209-30ECFD89FC8BQ40048210-D6C43010-A557-4786-AAA5-C459A339214CQ40105778-8D9438EE-051C-43D0-BFFB-E4CAEA5F17F0Q40177537-2E10F4F7-393B-4E8E-AED5-9A4E600FDF9BQ40351396-FAC45660-9339-4ACE-9519-8905F6E2AA51Q40811100-4C9993C4-F584-471C-B0C0-1F42F27900E1Q40999344-CB0DE177-4F6C-43F1-AC90-FC541B4D84F6Q42834858-06CB0DDA-F707-43A3-8507-B7717EAB2791Q44407120-0F04AF06-36C7-4AD7-9A3B-064120C67B27Q44661984-0FCA52D0-5234-4946-B1A7-0833E539AD24Q50111281-DD040019-7727-4386-A6D4-A62FF2C52891Q50356125-10FB8225-6BAC-4059-A05A-025F7620EF1FQ50434514-CBB118E4-D63C-4464-83CA-8D83C9701776
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marina Di Domenico
@ast
Marina Di Domenico
@en
Marina Di Domenico
@es
Marina Di Domenico
@nl
Marina Di Domenico
@sl
type
label
Marina Di Domenico
@ast
Marina Di Domenico
@en
Marina Di Domenico
@es
Marina Di Domenico
@nl
Marina Di Domenico
@sl
prefLabel
Marina Di Domenico
@ast
Marina Di Domenico
@en
Marina Di Domenico
@es
Marina Di Domenico
@nl
Marina Di Domenico
@sl
P106
P1153
7004590612
P21
P31
P496
0000-0002-6201-4200